ARA-290: Safeguarding Healthy Cells From Chemotherapy-Induced DNA Damage

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Summary

Emerging evidence positions ARA-290 (cibinetide)—a non-erythropoietic peptide engineered from erythropoietin (EPO)—as a tissue-protective agent with antigenotoxic, antioxidant, anti-inflammatory, and anti-apoptotic actions. In preclinical models, ARA-290 reduces doxorubicin (DOX)–induced DNA damage and oxidative stress in non-malignant cells without diminishing DOX’s anticancer activity. Mechanistically, ARA-290 selectively engages the innate repair receptor (IRR; EPOR–βcR heteroreceptor) and activates JAK2-dependent cytoprotective pathways while dampening NF-κB, p38 MAPK, and GSK-3β signaling. Beyond oncology support, ARA-290 shows multiorgan anti-inflammatory effects and early clinical safety signals (e.g., in diabetic macular edema), and may modulate monocyte subsets that clear amyloid in early Alzheimer’s models.

How ARA-290 Works: Targeted Tissue Protection Without Erythropoiesis

• Selective receptor engagement: ARA-290 binds the innate repair receptor (IRR), distinct from the classical erythropoietic EPO receptor, enabling tissue protection without hematologic/cardiovascular side effects associated with high-dose EPO.

• Cytoprotective signaling: IRR ligation activates JAK2 and downstream pro-survival programs; concurrently, it suppresses pro-inflammatory cascades (NF-κB transcriptional activity, p38 MAPK, GSK-3β) and promotes eNOS phosphorylation and related reparative signaling.

• Net effect: Reduced inflammatory tone and apoptosis, enhanced cellular stress resilience, and preservation of tissue integrity under cytotoxic pressure.
  

Genoprotection During Doxorubicin Exposure

Key preclinical findings (in vitro):

• Concentration-dependent genoprotection: ARA-290 lowers DOX-induced DNA damage—measured by comet assay (DNA in tail) and micronucleus frequency—across multiple non-malignant cell types.

• Oxidative-stress control: ARA-290 decreases ROS generation and restores antioxidant defenses, increasing superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities.

• Inflammation & apoptosis: ARA-290 attenuates DOX-evoked NF-κB activation and pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and counters TRAIL-sensitized apoptotic signaling—mechanisms implicated in chemotherapy-related tissue injury (including myocardium).
• Cardioprotection hypothesis: By limiting oxidative and inflammatory injury, ARA-290’s genoprotective profile may extend to cardiac cells, a primary site of DOX toxicity—warranting targeted in vivo validation.
  (1)

Protecting Normal Cells Without Blunting Anticancer Efficacy

• Tumor selectivity: Available data indicate functional EPO/IRR signaling is minimal in many tumors (very low EpoR transcripts relative to normal tissues), reducing the likelihood that ARA-290 shields cancer cells from DOX.

• Observed outcome: In comparative assays, ARA-290 preserved DOX cytotoxicity in cancer cell lines while improving viability and genomic integrity of non-malignant and stem/progenitor cells exposed to DOX. (1)

Multi-Organ Anti-Inflammatory Activity

In diverse animal models, erythropoietin-derived tissue-protective signaling (including ARA-290/cEPO analogs) consistently:

• Reduces leukocyte infiltration and down-modulates TNF-α, IL-1β, IFN-γ, IL-6;
  
• Boosts anti-inflammatory cytokines (IL-10, TGF-β);
  
• Mitigates sepsis-related NO overproduction and improves endothelial function;
  
• Attenuates neuroinflammation after brain injury and in autoimmune neuritis. (3)

Neuroimmune Modulation in Early Alzheimer’s Models

In APP/PS1 mice, early systemic ARA-290:

• Improved cognition and slowed amyloid-β (Aβ) pathology;
  
• Expanded Ly6C^low patrolling monocytes, enhancing vascular Aβ clearance and reducing overall brain Aβ burden;
  
• Increased monocyte progenitors in bone marrow.
  Timing matters: Effects were diminished in aged mice with advanced pathology, underscoring a window for early intervention. (2,5)

Early Clinical Signal: Diabetic Macular Edema (Phase 2)

In a 12-week study, cibinetide (ARA-290) was well tolerated and associated with improvements in vision-related quality of life, retinal thickness (CRT), tear production, and metabolic/renal markers in subsets of participants—supporting further trials. (4)

Practical Takeaways

• What it offers: ARA-290 is an investigational IRR agonist that limits chemotherapy-related DNA damage and oxidative stress in normal cells without impairing anticancer action in current preclinical assessments.

• Where it may fit: As a chemoprotective adjunct to reduce off-target toxicity (e.g., anthracyclines), and as a broader anti-inflammatory/tissue-protective agent under study (neurologic, vascular, ocular).

• Status & caution: Human data remain early-stage; dosing, timing, and long-term outcomes require controlled clinical trials. ARA-290 should be used for research only unless part of an approved study.
  

References 

(1) Shokrzadeh, Mohammad, et al. “An Engineered Non-Erythropoietic Erythropoietin-Derived Peptide, ARA290, Attenuates Doxorubicin Induced Genotoxicity and Oxidative Stress.” Toxicology in Vitro, vol. 66, 1 Aug. 2020, p. 104864, www.sciencedirect.com/science/article/abs/pii/S0887233320300783, 10.1016/j.tiv.2020.104864.

(2) Al-Onaizi, Mohammed A., et al. “FvEarly Monocyte Modulation by the Non-Erythropoietic Peptide ARA 290 Decelerates AD-like Pathology Progression.” Brain, Behavior, and Immunity, 31 July 2021, www.sciencedirect.com/science/article/abs/pii/S0889159121002804, 10.1016/j.bbi.2021.07.016.

(3) Silva, Inês, et al. “Potential Anti-Inflammatory Effect of Erythropoietin in Non-Clinical Studies in Vivo: A Systematic Review.” Biomedicine & Pharmacotherapy, vol. 139, 1 July 2021, p. 111558, www.sciencedirect.com/science/article/pii/S0753332221003437, 10.1016/j.biopha.2021.111558.

(4) Lois, Noemi, et al. “A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.” Journal of Clinical Medicine, vol. 9, no. 7, 14 July 2020, p. 2225, www.ncbi.nlm.nih.gov/pmc/articles/PMC7408632/, 10.3390/jcm9072225.

(5) Fani Maleki, Adham, and Serge Rivest. “Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer’s Disease and Multiple Sclerosis.” Frontiers in Cellular Neuroscience, vol. 13, 31 July 2019, 10.3389/fncel.2019.00355.

(6) “DNA Damage Response.” Www.rndsystems.com, www.rndsystems.com/resources/articles/dna-damage-response.